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Previous studies have indicated that human immunodeficiency virus type 1 (HIV-1) protease inhibitors (PIs)
are less active at blocking viral replication in HIV-1 infected peripheral blood monocytes/macrophages (M/M)
than in HIV-1-infected T cells. We explored the hypothesis that oxidative modification and/or metabolism of
the PIs in M/M might account for this reduced potency. We first tested the susceptibility of several PIs
(kynostatin-272 [KNI-272], saquinavir, indinavir, ritonavir, or JE-2147) to oxidation after exposure to hydro-
gen peroxide (H2O2): only KNI-272 was highly susceptible to oxidation. Treatment of KNI-272 with low
millimolar concentrations of H2O2 resulted in mono-oxidation of the sulfur in the S-methyl cysteine (me-
thioalanine) moiety, as determined by reversed-phase high-performance liquid chromatography and mass
spectrometry (RP-HPLC/MS). Higher concentrations of H2O2 led to an additional oxidation of the sulfur in the
thioproline moiety of KNI-272. None of the PIs were metabolized or oxidized when added to T cells and
cultured for up to 12 days. However, when KNI-272 was added to M/M, the concentration of the original
KNI-272 steadily decreased with a corresponding increase in the production of three KNI-272 metabolites as
identified by RP-HPLC/MS. The structures of these metabolites were different from those produced by H2O2
treatment. The two major products of M/M metabolism of KNI-272 were identified as isomeric forms of
KNI-272 oxidized solely on the thioproline ring. Both metabolites had reduced capacities to inhibit HIV-1
protease activity when tested in a standard HIV-1 protease assay. These studies demonstrate that antiviral
compounds can be susceptible to oxidative modification in M/M and that this can affect their antiviral potency.
Inhibitors of the human immunodeficiency virus type 1
(HIV-1) protease prevent the production of infectious virus by
blocking the function of virus-encoded aspartyl protease (28).
Inhibition of the protease leads to the production of noninfec-
tious immature virions containing uncleaved Gag and Gag-Pol
polyproteins (11, 19, 31). Several HIV-1 protease inhibitors
(PIs) are now in widespread clinical use and are highly potent
when used in combination with other anti-HIV agents (21, 36).
While highly active antiretroviral therapy can lead to undetect-
able plasma viral loads, there is increasing evidence that cells
of the monocyte/macrophage (M/M) lineage act as a host res-
ervoir for HIV (1, 5, 20, 34). Moreover, there is evidence that
PIs may have reduced activity in M/M and that smoldering
infection in such cells can act as viral reservoirs that lead to the
selection of resistant virus (28). It has been recognized that
there is a need to achieve more complete inhibition of viral rep-
lication in potential viral reservoirs, and there is interest in devel-
oping more effective methods to block HIV-1 replication in M/M.
In a previous study, we found that certain HIV-1 PIs were
less potent (higher 50% effective concentration) at blocking
HIV-1 production in M/M than in T cells (28). We hypothe-
sized that increased PI metabolism may occur, in part, as a
result of increased oxidative metabolism of the inhibitors. In
response to a variety of stimuli, M/M produce superoxide and
hydrogen peroxide (H2O2) by using the NADPH oxidase sys-
tem (25). In addition, M/M have an increased mitochondrial
oxidative metabolism compared to other cells (17). Therefore,
modification of the inhibitors could occur via reactive oxygen
intermediates (ROIs) generated by M/M or through oxidative
metabolism (28). Many HIV-1 PIs are metabolized through
oxidative pathways in vivo (8, 15, 18, 36, 37), and it seemed
possible that the PIs might also be oxidized by certain target
cells in HIV-infected patients.
Increased oxidative metabolism and the production of ROIs
by M/M occur after HIV-1 infection, possibly due to increased
exposure to cytokines and HIV-1-related antigens (2, 25, 26,
29). These ROIs have been reported to play an important role
in HIV-1 replication in M/M (26) and in enhancing the cell-
to-cell spread of virus (14). In addition a number of clinical
studies reveal that the overall redox state of HIV-1-infected
patients is altered to a more prooxidant state (2, 35). Together,
these studies indicate the presence of altered oxidative metab-
olism in HIV-1-infected M/M and in HIV-1-infected patients,
and we have hypothesized that this could have an impact on
the drugs that target HIV-1 replication, especially in M/M. An
examination of the structures of several PIs showed that cer-
tain of these agents have functional groups that could be sus-
ceptible to oxidation. To explore this possibility, we examined
the susceptibility of several PIs to oxidative modification and,
when such changes were observed, studied the metabolism of
the drugs in HIV-1-susceptible cells.
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MATERIALS AND METHODS
Chemicals. The PIs JE-2147 (22, 38), saquinavir (4), indinavir (3), and ritona-
vir (21) were obtained as gifts from Hiroaki Mitsuya (National Cancer Institute,
National Institutes of Health, Bethesda, Md.). Kynostatin-272 (KNI-272) (13)
was obtained from the Japan Energy Corporation. All inhibitors were stored at
20°C as 10 to 40 mM stock solutions in 100% dimethyl sulfoxide (DMSO).
Granulocyte-macrophage colony-stimulating factor (GM-CSF) and tissue necro-
sis factor alpha (TNF-) were obtained from R&D (Minneapolis, Minn.). Lipo-
polysaccharide (LPS) was obtained from Invitrogen (Gaithersburg, Md.).
Cells and culture conditions. Primary M/M were prepared and purified as
described previously (10). Briefly, peripheral blood mononuclear cells were ob-
tained from healthy HIV-1-negative donors through the Department of Trans-
fusion Medicine, Warren G. Magnuson Clinical Center (Bethesda, Md.). Cells
were separated over a Ficoll-Hypaque gradient and seeded in 25-cm2 tissue
culture flasks at a density of 3  107 cells/flask in complete medium consisting of
RPMI 1640 with 10% AB heat-inactivated human serum; 20% heat-inacti-
vated, low-endotoxin, mycoplasma-free fetal bovine serum; 4 mM L-glutamine;
50 U of penicillin/ml; and 50 mg of streptomycin/ml. Cultures were maintained
in 5% CO2 in air at 37°C. After 4 to 5 days in culture, cell monolayers were gently
washed three times with phosphate-buffered saline (calcium- and magnesium-
free) to remove nonadherent cells. Monolayers of M/M were then maintained on
the complete medium described above without human serum. The nonadherent
cell population removed during washing of the M/M monolayers was resus-
pended at 5  106 cells/ml and stimulated with phytohemagglutinin (PHA) for 2
days and then with interleukin-2 (IL-2) (10 ng/ml; R&D) in complete RPMI 1640
medium. Five days after culture of M/M or 3 days after PHA and IL-2 stimula-
tion of the peripheral blood T-cell population, the PIs were added into the cell
culture medium to assess metabolism of the inhibitors by these cells. In some
experiments, HIV-infected M/M were used. M/M were infected with HIV-1BaL
(Advanced Biotechnology, Inc., Columbia, Md.) at 50 ng of p24/ml, and periph-
eral blood T cells were infected with 50 ng of p24/ml of the HIV-1 HTLV-IIIB
isolate (30). Assays for p24 (RIA; Perkin-Elmer Life Sciences, Boston, Mass.)
released into the culture medium were done to verify infection before the
addition of the test compounds. At different time points an aliquot (250 l) of
the medium was removed to analyze the PI concentration and evidence of any
metabolites. The 250-l aliquot was added to 750 l of 8 M guanidine-HCl to
give a final concentration of 6 M guanidine-HCl. The guanidine-HCl was used to
inactivate any enzymes present in the media that could lead to further metabo-
lism and to denature proteins and release any protein-bound inhibitor prior to
reversed-phase high-pressure liquid chromatography (RP-HPLC) analysis.
These samples were stored at 20°C until further analysis by RP-HPLC.
H9, H9/IIIB, and Jurkat T cells were used in some experiments to assess the
metabolism of PIs. These cell lines were maintained in complete RPMI 1640
medium, with 15% fetal bovine serum as previously described (30). Cells were
plated at 105 cells per ml, and test compounds were then added to give a final
concentration of 5 or 10 M. On different days as indicated in the results, a
250-l sample of the medium was removed and added to 750 l of 8 M guani-
dine-HCl. These samples were stored at 20°C until further analysis by RP-
HPLC.
Oxidation of PIs with hydrogen peroxide. Stock solutions (40 to 100 mM) of
PIs in DMSO were diluted into phosphate-buffered saline at concentrations of 1
to 200 M. The samples were then incubated for 15 to 30 min at 42°C in the
presence of different concentrations (1 to 200 mM) of H2O2. Samples were then
analyzed directly by RP-HPLC as described below.
RP-HPLC analysis. RP-HPLC analysis was used to assess the susceptibility of
the PIs to oxidation by H2O2 and to assess metabolism of the PIs by M/M,
peripheral blood T cells, and the other cell lines. The samples (obtained from
PI-treated cells) in guanidine-HCl were first passed through a Microcon-10
filtration device (Amicon, Beverly, Mass.) to remove proteinaceous and cellular
debris. The flowthrough containing the PI was then analyzed by RP-HPLC on a
Vydac (Resolution Systems, Holland, Mich.) C18 column (0.21 by 5 cm). Samples
were eluted from the column over a period of 25 min at a flow rate of 0.3 ml/min
with a linear gradient of 2.5 to 52.5% acetonitrile in 0.05% trifluoroacetic acid
(TFA) and water. The eluate was monitored with a multiwavelength diode array
detector with specific monitoring at 205, 276, and 350 nm. The inhibitor con-
centrations were calculated by using a standard curve obtained with different
concentrations of inhibitor in the tested range of 0.5 to 10 M diluted from stock
solutions into 6 M guanidine-HCl. Metabolites were purified by collecting the
eluting peak from RP-HPLC, lyophilized, resuspended in 10% DMSO, and then
analyzed by liquid chromatography-mass spectrometry (LC/MS). Medium ex-
tracts were subjected to LC/MS directly to identify the metabolites.
Methionine sulfoxide reductase treatment of oxidized KNI-272. KNI-272 ox-
idized at the S-methyl cysteine residue was purified by RP-HPLC as described
above and used in assays with purified recombinant yeast methionine sulfoxide
reductase EC 1.8.4.6 (MsrA) to determine whether the oxidized form could be
reduced by this enzyme. Oxidized KNI-272 dissolved in 3% DMSO was incu-
bated at a final concentration of 5 M in 150 mM sodium phosphate buffer (pH
8.0), 20 mM dithiothreitol (DTT), and 0.5 mM EDTA with or without MsrA at
170 g/ml isolated as described previously (23). The samples were then incu-
bated for 30 min at 37°C, at which time they were stopped by acidification with
5 l of 10% trifluoroacetic acid. Prior to RP-HPLC analysis, the sample was
diluted with a solution of 8 M guanidine to bring the sample to a final concen-
tration of 6 M guanidine, which was necessary for good recovery of the oxidized
and reduced forms of KNI-272.
Enzymatic assays. HIV-1 protease activity was determined as described pre-
viously (6). Briefly, HIV-1HXB2 protease at a final dimeric concentration of 200
nM was incubated in 40 l of protease assay buffer (150 mM sodium acetate, pH
5.7; 10% glycerol; 5% ethylene glycol; 1 mM EDTA) in the presence of the test
compounds dissolved in DMSO. After a 5-min preincubation, a 9-amino-acid
peptide substrate (dissolved in distilled water) spanning the matrix capsid cleav-
age site in gag was added at a final concentration of 3 mM and incubated for 5
to 10 min. The assay was stopped with an aliquot of 10% TFA, and the cleavage
products were quantified by RP-HPLC as described previously (6).
MS. Capillary HPLC was performed with a HP1100 binary gradient pump
(Agilent Technologies, Palo Alto, Calif.), operating at 100 l/min. An Accurate
AC-100-VAR flow splitter (LC Packings, San Francisco, Calif.), fitted with a
CAL-100-0.3 calibrator, reduced the flow being delivered to a C18 capillary
column (100 by 0.3 mm, 5 m; Keystone Scientific, Bellefonte, Pa.) to ca. 5
l/min. Solvent A was a 95:5:0.1 mixture of water, acetonitrile, and formic acid,
and solvent B was a 95:5:0.1 mixture of acetonitrile, isopropanol, and formic acid.
Next, 10 l of each sample (5 g) was desalted with C18 Ziptips (Millipore,
Bedford, Mass.), according to the manufacturer’s instructions. A 2-l sample was
injected and eluted by the following mixed-gradient method: 100% solvent A
held for 5 min, switched to 20% solvent B, followed by a gradient from 20 to 30%
solvent B for 20 min, followed by 30% solvent B held for 5 min, and then a
gradient from 30 to 95% solvent B for 5 min. The eluent flowed directly into a
Finnigan LCQ (ThermoQuest, San Jose, Calif.) for mass analysis. No sheath or
auxiliary gases were used, and the voltage was applied directly to the eluent.
Centroid LC/MS data were collected with the triple-play method (full-scan,
high-resolution zoom scan; mass spectrometry-mass spectrometry [MS/MS]) by
using the Xcalibur Software package.
RESULTS
Susceptibility of PIs to oxidation by hydrogen peroxide. To
assess the potential for different PIs (saquinavir, indinavir,
ritonoavir, JE-2147, and KNI-272) to be modified by oxidation,
we tested their susceptibility to modification by hydrogen per-
oxide (H2O2). Saquinavir, ritonoavir, and KNI-272 were cho-
sen since they had been shown previously by our group to be
less effective as inhibitors in M/M than in infected T cells (28).
The activity of these drugs in chronically infected M/M was 2-
to 10-fold lower than for infected T-cell lines, and it was sug-
gested that this may be due to increased oxidative modification
by M/M. JE-2147 was chosen because it is an allophyenyl-
norstatin-containing inhibitor similar to KNI-272 and was re-
cently developed to inhibit highly resistant HIV-1 isolates (38),
although the comparative activity of JE-2147 in infected M/M
cultures and infected T cells is unknown (38). Treatment with
high concentrations of H2O2 (100 mM) resulted in evidence of
modification of saquinavir, JE-2147, and KNI-272, as indicated
by RP-HPLC analysis (data not shown). The mass of JE-2147
increased by 32 after treatment with high concentrations (100
mM) of H2O2, and this indicated dioxidation of the compound
(data not shown). Although we did not further characterize the
nature of this oxidation, it is likely that oxidation occurred on
the sulfur of the thioproline moiety.
KNI-272 was clearly more sensitive to modification by H2O2
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than the other PIs, as indicated by RP-HPLC analysis. After
treatment of KNI-272 with H2O2 there were several new peaks
detected that eluted earlier than untreated KNI-272 (Fig. 1,
top). The majority of KNI-272 was converted to a doublet peak
eluting at 18.9 and 19.1 min designated P1 (Fig. 1, top). In
addition, there were four closely eluting peaks between 17 and
18 min designated P2 (Fig. 1, top). KNI-272 (Fig. 1A) would be
predicted to be most susceptible to oxidation at the sulfur in
the thioproline ring and/or the sulfur in the S-methyl cysteine
moiety yielding the sulfoxides. To determine the nature of the
oxidations, the new peaks generated after H2O2 treatment
were subjected to MS/MS analysis and compared to untreated
KNI-272. After MS/MS of untreated KNI-272 (MH  668)
we detect an m/z fragment ion of 452 that shows a loss of 216,
representing the thioproline ring-containing fragment (Fig. 2).
If the thioproline sulfur becomes oxidized, then we would
detect an m/z ion of 452 as with native KNI-272 but with a loss
of 232 (216  16) from the original mass of 684 (668  16)
representing the thioproline oxidized fragment (Fig. 2, path a).
Alternatively, if the methioalanine sulfur becomes oxidized
after treatment, one would predict an unfragmented m/z of 684
and an m/z fragment ion of 468 (452  16) and a loss of 216 via
path a (Fig. 2). These fragments would also show a loss of 64
(48  16) via path b (Fig. 2), representing the oxidized methyl
sulfur fragment. Indeed, these were the fragments detected
after MS/MS analysis of P1 eluting at 18.9 and 19.1 min on
RP-HPLC, demonstrating that P1 represented KNI-272 oxi-
dized only at the S-methyl cysteine sulfur (Fig. 1B). Since the
nonspecific oxidation of the S-methyl cysteine sulfur with hy-
drogen peroxide would be expected to yield both the R and S
FIG. 2. Schematic diagram indicating the important fragmentation
paths for fragmentation of KNI-272 after MS/MS analysis that allowed
us to assign the sites of oxidation. Path a provides information for the
determination of the oxidation state of the thioproline. Path b provides
information for the determination of the oxidation state of the S-
methyl cysteine. Numbers in parentheses represent the expected mo-
lecular weights if the sulfur in the fragment is oxidized.
FIG. 1. RP-HPLC analysis and chemical structures for KNI-272
and its oxidized forms generated by treatment with hydrogen peroxide.
(Top) RP-HPLC tracing of KNI-272 after treatment with 10 mM
H2O2. KNI-272 and the oxidized products, P1 and P2, are indicated in
the RP-HPLC tracing. Structures: A, KNI-272; B, KNI-272 oxidized at
the sulfur in the S-methyl cysteine moiety; C, KNI-272 oxidized on the
sulfur of the S-methyl cysteine residue and on the sulfur in the thio-
proline ring.
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configurations of the sulfoxide, it is likely that the doublet peak
represents these two epimers. To explore this possibility fur-
ther, we purified the material eluting as a doublet and treated
it with MsrA. It has been reported that MsrA only reduces the
S forms of methionine sulfoxide (24). RP-HPLC analysis of the
P1 doublet after treatment with MsrA demonstrated that only
the later eluting form of the doublet peak could be reduced
back to native KNI-272 (Fig. 3). This indicates that the doublet
peak represents two epimeric forms of KNI-272 (see Fig. 1B),
oxidized at the S-methyl cysteine residue (either R or S) that
are generated after treatment of KNI-272 with H2O2.
The other oxidation products of KNI-272 after treatment
with H2O2 and represented by the four closely eluting peaks on
RP-HPLC were also subjected to MS/MS analysis. Each of
these peaks was 32 Da greater than KNI-272 (MH  700).
The fragmentation results from MS/MS analysis were consis-
tent with these four peaks representing KNI-272 oxidized at
both the S-methyl cysteine residue and the thioproline ring.
There are four possible forms of P2 which likely represent the
four peaks: the R and S sulfoxides on S-methyl cysteine and the
R and S sulfoxides on the thioproline, thus generating the RR,
RS, SS, and SR sulfoxide forms of P2 (Fig. 1C). Interestingly,
hydrogen peroxide treatment of KNI-272 did not generate
KNI-272 oxidized solely on the thioproline ring.
KNI-272 is metabolized by M/M but not by T cells. In the
presence of M/M, the concentration of KNI-272, but not those
of the other inhibitors, decreased steadily over the 12-day
period tested. During this time, there was a steady increase in
the concentration of three metabolites (Fig. 4). Data from
several experiments in which ca. 5 million M/M (the adherent
cells) were cultured in 8 ml of medium indicated that the
concentration of the parent compound, KNI-272, decreased 30
to 50% by day 4 from the initial concentration of 10 M and
was barely detectable after 12 days (Fig. 4). Considering the
relatively small volume occupied by the macrophages, relative
to the total volume of the cultures, this rate of metabolism of
KNI-272 by the cells appears to be substantial. We hypothe-
sized that because of this intracellular metabolism of KNI-272,
the concentration of unmetabolized drug in the cells would be
less than in the media during the culture period. However, we
were unable to successfully measure the intracellular concen-
trations of drug due to the large number of M/M required for
the analysis.
As determined by RP-HPLC analysis, the initial decrease in
KNI-272 corresponded with the appearance of two new me-
tabolites (designated here as M1 and M2), with both eluting
earlier than native KNI-272 (Fig. 4). In addition, M1 and M2
retained the characteristic UV spectrum of KNI-272 with ab-
sorbance maxima at 220, 260, and 340 nm showing that there
were no modifications near the aromatic rings. M1 had a re-
tention time of 18.6 min and a mass of 683, which is equivalent
to the mass of KNI-272 containing an additional oxygen atom.
LC/MS/MS analysis of M1 identified this peak as correspond-
ing to KNI-272 oxidized only at the sulfur residue of the thio-
proline ring because of its loss of 232 Da via path a and its loss
of 48 Da via path b (see Fig. 2). M2, which had a retention time
of 19.1 min, also had a mass of 683 and had the same frag-
mentation pattern as M1, again indicating it to be KNI-272
oxidized solely at the sulfur residue in the thioproline ring.
This indicates that both the R and S configurations at the
thioproline sulfoxide epimeric center were produced when
KNI-272 was exposed to M/M cultures. KNI-272 oxidized at
the S-methyl cysteine residue (P1) was detected at low levels by
LC/MS/MS and eluted between the two thioproline oxidized
products on RP-HPLC. Surprisingly, the S-methyl cysteine ox-
FIG. 3. RP-HPLC analysis of purified oxidized KNI-272 (S-methyl
cysteine sulfoxide) before and after treatment with MsrA. Oxidized
KNI-272 was purified by RP-HPLC, incubated in the presence of 20
mM DTT, and then treated with or without MsrA as described in
Materials and Methods. After treatment, the sample was analyzed by
RP-HPLC. Curves: ——, without MsrA; – – –, with MsrA. The loca-
tions of oxidized and unoxidized KNI-272 are indicated.
FIG. 4. RP-HPLC analysis of medium extracts from KNI-272-
treated M/M at different time points. (A) The peaks corresponding to
KNI-272 and metabolites M1, M2, and M3 are indicated. (B) Structure
of M1 and M2 as determined by MS. M1 and M2 were produced after
addition of KNI-272 to macrophages. KNI-272 is oxidized at the thio-
proline ring in both M1 and M2 but in different epimeric configura-
tions.
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idized form did not represent a major metabolite of KNI-272,
even though this was the predominant form generated after
hydrogen peroxide treatment. A third major metabolite (des-
ignated M3), which eluted later than KNI-272 (Fig. 4) with a
retention time of 21.5 min, also had a mass of 683, again
indicating an oxidized form of KNI-272. LC/MS/MS analysis
showed a loss of 216 Da via path a (Fig. 2), indicating that
oxidation did not occur on the thioproline. While we were not
able to ascertain by MS/MS the site of oxidation in M3, the
later retention time compared to the native KNI-272 is indic-
ative of the ring being oxidized adjacent to the nitrogen gen-
erating a neutral, less-polar form of KNI-272. In addition, the
loss of 64 Da via path b, which is characteristic of S-methyl
cysteine oxidation, was absent. M3 had an altered UV spec-
trum compared to KNI-272 with a shift in absorbance maxima
in the UV from 245 nm to 270 nm. This shift in the absorbance
maxima would be consistent with KNI-272 oxidized on the
isoquinol moiety. To determine whether the PIs were oxidized
in cells that are susceptible to HIV infection, we treated pe-
ripheral blood T cells, H9, H9/HTLVIIIB, and Jurkat T cells or
human M/M with the different PIs and then analyzed the
media for the production of metabolites. The cells were incu-
bated in the presence of each protease inhibitor, and aliquots
of the cell culture media were taken at different time points
and analyzed by RP-HPLC. We did not detect metabolites of
any of the inhibitors after more than 10 days of incubation with
peripheral blood T cells, H9, H9/HTLVIIIB, or Jurkat cells
(data not shown). In addition, there was no measurable de-
crease in the concentration of each tested inhibitor, including
KNI-272, after a 10-day incubation, suggesting that these com-
pounds were highly stable in these cell types.
Time course of M1, M2, and M3 production by M/M after
treatment with KNI-272. In the presence of M/M, the metab-
olites of KNI-272, M1 and M2, were detected within 2 days and
steadily increased up to day 12 (Fig. 5). M1 was the major
metabolite, followed by M2 and M3. M3 was first detected on
day 4 and steadily increased over 12 days. By day 12 90% of
the KNI-272 was metabolized to other products by the M/M.
By day 12, the metabolites M1, M2, and M3 accounted for a
little more than 50% of the original KNI-272. This suggests
that further metabolism of the oxidized forms of KNI-272
likely occurs in M/M.
We tested a number of conditions reported to activate the
oxidative burst in cells to determine whether the level of oxi-
dative stress might influence the extent at which M/M metab-
olized KNI-272. HIV infection is thought to increase oxidative
stress (27), so we first compared the ability of uninfected and
HIV-infected M/M to metabolize KNI-272 to M1, M2, and
M3. However, there was little difference in the rate or extent of
KNI-272 metabolism between the two conditions tested (data
not shown). We also sought to determine whether GM-CSF,
TNF-, and LPS affected the extent of KNI-272 metabolism
since these agents have been shown to elicit oxidative stress in
cells (9, 32, 33). After 1 day, untreated macrophages metabo-
lized ca. 6% of the KNI-272 added (Fig. 6). However, the
percentage of KNI-272 metabolized increased to 13 and 26% 1
day after addition of KNI-272 to the cells treated with 10 ng of
GM-CSF or 1 ng of TNF-/ml, respectively (Fig. 6). LPS at 25
ng/ml or higher, however, did not increase the percentage of
KNI-272 metabolized and was found to decrease the rate of
metabolism two or more days after treatment (Fig. 6 and data
not shown).
FIG. 5. Time course of KNI-272 metabolism in media by M/M.
Approximately 5 million M/M (the adherent cells from 30 million
plated cells) were cultured in 8 ml of medium, to which was added
KNI-272 at a final concentration of 10 M. Small aliquots of the media
were periodically removed and analyzed for KNI-272 and metabolites
M1, M2, and M3 by RP-HPLC as described in Materials and Methods.
Symbols: f, KNI-272; F, M1; Œ, M2; and }, M3.
FIG. 6. Effect of GM-CSF, TNF-, or LPS on KNI-272 metabolism
in macrophages. Cultures of M/M in medium to which KNI-272 had
been added at a final concentration of 10 M were cultured as as in
Fig. 5. Aliquots (250 ml) were withdrawn at days 0, 1, and 2, and the
concentration of the remaining KNI-272 was determined as described
in Materials and Methods.
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Comparison of the inhibition of HIV-1 protease activity by
KNI-272 and its metabolites derived from M/M. To determine
whether the oxidation of KNI-272 by M/M affected its potency
as an HIV-1 protease inhibitor, we purified native KNI-272
and the major oxidized forms (M1 and M2) by RP-HPLC from
medium extracts of treated M/M. The identity of the com-
pounds was first verified by MS analysis, the concentration was
determined by RP-HPLC analysis, and then the purified com-
pounds were tested in a standard HIV-1 protease assay. As
shown in Fig. 7, the inhibitory activity of M1 and M2 was
impaired compared to that of native KNI-272. The calculated
50% inhibitory concentrations for KNI-272, M1, and M2, were
8, 45, and 16 nM, respectively. KNI-272 at 30 nM decreased
protease activity by 90% compared to decreases of 50 and
75% with 30 nM M1 and M2, respectively (Fig. 7).
DISCUSSION
The ability of various HIV-1 PIs to block HIV-1 replication
in infected M/M is decreased compared to that for infected T
cells (28). In this study, we investigated the degree to which PIs
were metabolized by peripheral blood T cells, T-cell lines, and
M/M to determine whether this might account for the observed
differences in antiviral activity. We were particularly interested
in the susceptibility of PIs to oxidative metabolism since M/M
are known to generate a number of ROIs that could modify the
inhibitors. Although some of the inhibitors (saquinavir, JE-
2147, and KNI-272) contained functional groups that were
susceptible to oxidation in vitro with H2O2, only one of these,
KNI-272, was substantially affected when treated with H2O2 or
added to M/M. KNI-272 was readily oxidized at the S-methyl
cysteine moiety (R and S configurations of S-methyl cysteine
sulfoxide) after hydrogen peroxide treatment, while oxidation
of KNI-272 in the presence of M/M occurred predominantly at
the thioproline ring, once again without stereospecificity. In
addition, the primary macrophage-derived metabolites of KNI-
272, M1 and M2, were less active as inhibitors of the HIV-1
protease compared to KNI-272. In contrast, KNI-272 and the
other inhibitors were not metabolized when they were incu-
bated with peripheral blood T cells or various T-cell lines for
up to 12 days. Therefore, differences in oxidative metabolism
by M/M compared to T cells could explain the reduced potency
of KNI-272 in M/M, although there are apparently other ex-
planations for the decrease in potency of the other PIs when
tested in M/M.
The mechanism by which KNI-272 is oxidized and/or me-
tabolized by M/M was not directly addressed in this study.
Kiriyama et al. found three major metabolites when they mea-
sured the metabolism of KNI-272 in rat liver microsomes ex-
posed to KNI-272 (15). The production of these three metab-
olites was NADPH dependent and was inhibited in the
presence of the P450 monooxygenase inhibitor, ketoconazole.
These metabolites which were not identified were presumably
oxidized forms of KNI-272 and may be similar if not identical
to the ones that we have identified here by LC/MS analysis.
M/M may metabolize KNI-272 through a P450 monooxygenase
pathway or by an NADPH oxidase system. Interestingly, the
percentage of KNI-272 metabolized after just 1 day was in-
creased from two- to sixfold when the cells were treated with
GM-CSF or TNF-. This suggests that activating oxidative
stress with various agents may further increase the extent of
metabolism of protease inhibitors. These agents are known to
activate NADPH oxidase and this would suggest that superox-
ide produced from this system may be involved in the metab-
olism of KNI-272.
The S-methyl cysteine moiety of KNI-272 was found to be
more sensitive to hydrogen peroxide oxidation than the thio-
proline moiety. Indeed, we even detected low levels of oxida-
tion of S-methyl cysteine in stored samples of KNI-272 (data
not shown). However, the S-methyl cysteine oxidized form of
KNI-272 did not accumulate to any great degree when KNI-
272 was added to M/M. In contrast, the thioproline group was
substantially oxidized. Interestingly, thioproline itself is a
known antioxidant shown to improve macrophage function.
Therefore, the thioproline within KNI-272 probably reacts
with ROIs in a similar way.
We found that M/M oxidatively modified KNI-272 while
other cell types did not. This is consistent with other studies
indicating that the oxidative environment of M/M is different
from that of T cells and other cell types (16). Such differences
in the oxidative environment can also affect HIV-1 replication.
We previously reported that the activity of HIV-1 protease can
be affected by oxidative conditions, and we suggested (28) that
the oxidative environment of M/M may favor the production of
a more active glutathionylated form of the HIV-1 protease (6,
7). These effects of oxidative conditions on HIV-1 protease
may provide a reason why HIV-1-infected M/M require higher
concentrations of PIs to reach similar levels of inhibition com-
pared to HIV-1-infected T cells. In addition, the present ob-
servation that M/M and T cells can differentially metabolize a
potent PI may provide another possible mechanism for de-
creased PI activity in M/M. It is unclear whether the metabo-
lism of KNI-272 under oxidative conditions contributed to the
relatively poor activity of this compound in clinical testing (12).
While the decline in KNI-272 concentration in the media in
cultures of M/M (ca. 5 million cells in 8 ml of medium) was
relatively slow, it should be remembered that the total intra-
cellular volume of the M/M in the cultures was only a small
fraction of the total volume of media. We were unable to assay
FIG. 7. HIV-1 protease activity in the presence of increasing con-
centrations of KNI-272 and M1 and M2 (KNI-272 metabolites). Each
compound was separated and purified by RP-HPLC. The compounds
were dissolved in DMSO and then tested for inhibitory activity toward
the HIV-1 protease as described in Materials and Methods. Each point
represents the mean of three independent measurements  the stan-
dard deviation. Symbols: }, KNI-272; f, M1; and Œ, M2.
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the intracellular concentration of KNI-272 in the M/M but
would expect these levels to be substantially lower than that in
the medium. Thus, metabolism of susceptible protease inhib-
itors is likely to result in lower intracellular levels in M/M than
in serum, and the results of the present study suggest that when
developing novel antiviral therapies one should consider the
possibility that metabolism by target cells under oxidative con-
ditions may lead to altered activity. In particular, it will be of
importance to assess the fate of potentially useful antiviral
compounds in M/M and M/M exposed to various immune
activating agents.
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